The self-administered psoriasis area and severity index is valid and reliable.
about
Complementary therapies for chronic plaque psoriasisMeasures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnPsoriasis and Atopic Dermatitis.Evaluation of efalizumab using safe psoriasis control.Exploring the link between cadmium and psoriasis in a nationally representative sampleClinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality.Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study).Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasisOverview of psoriasis.Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis.Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis.The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.Current severe psoriasis and the rule of tens.Severity and management of psoriasis within primary care.The Relationship between Disease, Work and Sickness Absence among Psoriasis Patients.Epidemiology of psoriasis. Review and the German perspective.Measuring disease activity in psoriatic arthritis.The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.Quality of life of psoriasis patients before and after balneo -- or balneophototherapy.Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).Primary care-based screening for cardiovascular risk factors in patients with psoriasis.Patient involvement in outcome measures for psoriatic arthritis.Systematic review of cost-effectiveness analyses of treatments for psoriasis.Patient-reported outcome measures in psoriasis: the good, the bad and the missing!Agreeableness and Self-Consciousness as Predictors of Induced Scratching and Itch in Patients with Psoriasis.Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea.Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP).The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability.Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study.Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis.Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study.An Italian study on psoriasis and depression.The evaluation of family impact of recessive dystrophic epidermolysis bullosa using the Italian version of the Family Dermatology Life Quality Index.Patients' experience of psoriasis in the genital area.Atopic dermatitis -- topical therapy: do patients apply much too little?Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities.A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis.Emotion Regulation in Patients with Psoriasis: Correlates of Disability, Clinical Dimensions, and Psychopathology Symptoms.Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.
P2860
Q24194968-2BDCDEF9-76AC-482A-905A-4B9BF233B6FCQ26862017-860D5A37-169A-4FE6-8D8E-67E50B131EBBQ30238648-083C2FEC-18E0-49D5-A597-93019339FB68Q33258048-2FCCFB0E-A91E-4305-A71F-E92BA625EE87Q33687498-648ED5CF-B0E9-4D0A-BF85-0F1141F1213FQ33723592-F5CFAF04-6BE7-4E63-9C7C-9B476F170D64Q33802843-60F3BBC3-B1BC-4CE3-8313-C459D5D61BF4Q33879351-056C79D7-0D57-49F9-B4C6-D0FE72D24B53Q34551058-0FA9ACED-28E1-4547-AA1E-E3C9A17FAB2EQ34564453-9800F12B-FCA7-4D2E-866B-0A055EF0EE92Q35892185-77558127-0FD5-49F3-A98D-E04E3BECB7FDQ36077729-3F267D12-CA2C-43BE-8BAA-1B2662AD0F74Q36124195-47F246FB-7AEA-4AA0-8461-472AD62E106EQ36163078-F5ACFAA5-F75C-4188-AEEB-C32C52145B77Q36436098-44B39F0A-D43E-4885-A057-95DC2780DB3BQ36481432-0CD5EA34-D4F6-4338-95B0-795DB814D771Q36520126-D862C7E9-877F-4B70-BCDE-9F2C945A8A9DQ36602668-5DD5FFEC-ADF7-4AE0-B790-0F50A7E9146EQ37006640-6D2ECC81-3EF3-441D-9619-43FC932B87A4Q37183266-5C3ACC07-BC00-427F-BA02-14A3F12CBBD0Q37184480-FB5EBC2C-AE87-490A-BBFC-6D0E3293EC15Q37420435-C996C9AF-5486-406B-9705-01735F93AE32Q38195568-FF9340C8-A33F-47D9-B128-EE2744C1F99FQ38283299-BE538D09-49DB-4D21-B1E4-1CDB43206E84Q38354062-6DC5AEA6-39BF-4159-8E93-0BDAC7CD35BAQ39031065-3270B17F-6935-4AC1-9048-38DE344B2710Q39046278-FCFF3EDF-D966-415D-A585-39B8EA7CAC8BQ39189237-EA2777C7-388A-4BE3-8E00-5FADD09508D9Q40443395-26C286CA-871E-43A8-B079-0C7D86E1D78EQ40619262-33F90B9E-9C20-4553-AE47-F68C2F57516EQ40977555-7AD025BF-E323-4AD2-A1DC-15257ED27CD3Q43574657-D28B1E96-25BD-4DF4-9F56-CB85309D4B18Q45101688-4774E3B0-8091-40F6-B9E6-E3A31DAB1801Q45779234-1D9059CA-C37A-46AC-BA3E-DCD4591EFBB2Q46066598-33A0FF0E-9A63-457F-8F6E-22C445D34CD8Q46600782-E5161139-E4CF-4E97-8D1C-4FE2DF0305C6Q46703507-F51555FB-0484-4A9E-84AC-079B7267D519Q46915226-EC113F18-156C-4F0A-8071-7FE72AF9B5FEQ47365469-8820AF9C-697C-4A8E-9D24-A1DED66CF44FQ47591118-99A9361C-6005-4F5A-9BBF-57A837025170
P2860
The self-administered psoriasis area and severity index is valid and reliable.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
The self-administered psoriasis area and severity index is valid and reliable.
@ast
The self-administered psoriasis area and severity index is valid and reliable.
@en
The self-administered psoriasis area and severity index is valid and reliable.
@nl
type
label
The self-administered psoriasis area and severity index is valid and reliable.
@ast
The self-administered psoriasis area and severity index is valid and reliable.
@en
The self-administered psoriasis area and severity index is valid and reliable.
@nl
prefLabel
The self-administered psoriasis area and severity index is valid and reliable.
@ast
The self-administered psoriasis area and severity index is valid and reliable.
@en
The self-administered psoriasis area and severity index is valid and reliable.
@nl
P2093
P1476
The self-administered psoriasis area and severity index is valid and reliable.
@en
P2093
Feldman SR
Fleischer AB Jr
Reboussin DM
P2888
P304
P356
10.1111/1523-1747.EP12329912
P407
P577
1996-01-01T00:00:00Z
P5875
P6179
1025720107